| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| XOMA Corp | CEO, Director | Depositary Shares - 8.375% B Cumulative Stock | 8K | $190K | $23.79 | Jul 15, 2022 | By spouse |
| XOMA Corp | CEO, Director | Common Stock | 11.8K | $164K | $13.89 | Jul 15, 2022 | Direct |
| XOMA Corp | CEO, Director | Common Stock | 5.56K | $77.2K | $13.89 | Jul 15, 2022 | By 401(k) Plan |
| Akari Therapeutics Plc | Director | Ordinary Shares, par value $0.0001 per share | 22.2M | $26.7K | $0.00 | Nov 14, 2024 | Direct |
| PALISADE BIO, INC. | Director | Common Stock, par value $0.01 | 10.9K | $4.76K | $0.44 | Feb 9, 2024 | Direct |
| PALISADE BIO, INC. | Director | Restricted Stock Units | 0 | $0 | $0.44 | Feb 9, 2024 | Direct |
| Peak Bio, Inc. | Director | Common Stock | 0 | $0 | $0.27 | Nov 14, 2024 | Direct |
| XOMA Corp | CEO, Director | Stock Option (Right to Buy) | 218K | Jul 15, 2022 | Direct | ||
| Monterey Bio Acquisition Corp | Director | Common Stock | 35K | Sep 30, 2021 | Direct | ||
| Processa Pharmaceuticals, Inc. | Director | Restricted Stock | 31.2K | Sep 3, 2024 | Direct | ||
| XOMA Corp | CEO, Director | 8.625% Series A Cumulative Perpetual Preferred Stock | 8K | Jul 15, 2022 | By spouse | ||
| PALISADE BIO, INC. | Director | Common Stock Options | 6.88K | Feb 9, 2024 | Direct | ||
| Peak Bio, Inc. | Director | Convertible Notes | 0 | Nov 14, 2024 | Direct | ||
| Peak Bio, Inc. | Director | Stock Option (Right to Buy) | 0 | Nov 14, 2024 | Direct | ||
| Peak Bio, Inc. | Director | Warrant (Right to Purchase) | 0 | Nov 14, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | Nov 14, 2024 | 0 | $0 | 3 | Nov 22, 2024 | Director |
| PKBO | Peak Bio, Inc. | Nov 14, 2024 | 5 | -$20K | 4 | Nov 18, 2024 | Director |
| PCSA | Processa Pharmaceuticals, Inc. | Sep 3, 2024 | 1 | $0 | 4 | Sep 18, 2024 | Director |
| PALI | PALISADE BIO, INC. | Feb 9, 2024 | 8 | $0 | 4 | Feb 13, 2024 | Director |
| PALI | PALISADE BIO, INC. | Nov 21, 2023 | 2 | $0 | 4 | Nov 24, 2023 | Director |
| PCSA | Processa Pharmaceuticals, Inc. | Jun 27, 2023 | 3 | $0 | 4 | Jul 24, 2023 | Director |
| PALI | PALISADE BIO, INC. | Jun 11, 2023 | 2 | $0 | 4 | Jun 13, 2023 | Director |
| PKBO | Peak Bio, Inc. | Apr 28, 2023 | 2 | $20K | 4 | May 2, 2023 | Director |
| PKBO | Peak Bio, Inc. | Nov 1, 2022 | 0 | $0 | 3 | Nov 3, 2022 | Director |
| PCSA | Processa Pharmaceuticals, Inc. | Jul 19, 2022 | 1 | $0 | 4 | Jul 21, 2022 | Director |
| PCSA | Processa Pharmaceuticals, Inc. | Jul 19, 2022 | 0 | $0 | 3 | Jul 21, 2022 | Director |
| XOMA | XOMA Corp | Jul 15, 2022 | 5 | -$645K | 4 | Jul 18, 2022 | CEO, Director |
| XOMA | XOMA Corp | Mar 21, 2022 | 9 | -$1.34M | 4 | Mar 23, 2022 | CEO, Director |
| XOMA | XOMA Corp | Dec 21, 2021 | 1 | $0 | 4 | Dec 23, 2021 | CEO, Director |
| PALI | PALISADE BIO, INC. | Nov 18, 2021 | 1 | $0 | 4 | Feb 10, 2022 | Director |
| MTRY | Monterey Bio Acquisition Corp | Sep 30, 2021 | 0 | $0 | 3 | Sep 30, 2021 | Director |
| XOMA | XOMA Corp | Jun 25, 2021 | 3 | -$303K | 4 | Jun 29, 2021 | CEO, Director |